LivaNova PLC
LIVNHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeLivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the. The $4.05B market capitalization puts LIVN squarely in mid-cap range for its industry. The company operates in two segments, Cardiopulmonary and Neuromodulation.
Market Cap
$4.05B
Beta
0.82
P/E (TTM)
37.65
P/E (Fwd)
15.94
EPS (TTM)
$1.96
EPS (Fwd)
$4.63
ROE
9.5%
ROA
5.3%
Cash
$539.7M
Total Debt
$343.4M
Free CF
$198.1M
52W Change
70.0%
Annual Financials
Cash vs Debt
With $539.7M in cash and $343.4M in debt, LIVN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $198.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 9.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.02B (2022) to $1.39B (2025), reflecting a 36% increase over the period.
As with any equity investment, LIVN carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing LIVN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.